flad-1 Antibody

What is FLAD1 and why is it important in research?

FLAD1 is a protein-coding gene for flavin adenine dinucleotide synthetase (FADS), a key enzyme in the FAD biosynthesis process which contains an N-terminal molybdopterin-binding (MPTb) domain and a C-terminal domain (FADS domain) . The enzyme plays a crucial role in cellular metabolism as FAD is an essential cofactor for numerous biological processes. The importance of FLAD1 in research stems from its association with multiple pathological conditions, including metabolic disorders like Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) and its potential role as a biomarker in various cancers, particularly breast cancer . Understanding FLAD1 expression and function can provide insights into both disease mechanisms and potential therapeutic targets.

What applications are recommended for FLAD1 antibodies?

FLAD1 antibodies have been validated for multiple experimental applications, with specific dilution recommendations for optimal results. For Western Blot (WB) applications, a dilution range of 1:500-1:1000 is recommended . For immunofluorescence (IF) and immunocytochemistry (ICC) applications, a dilution range of 1:200-1:800 is recommended . Additionally, FLAD1 antibodies have been successfully used in co-immunoprecipitation (CoIP) and ELISA applications . It is important to note that optimal dilutions may be sample-dependent, and researchers should consider titrating the antibody in their specific testing systems to achieve optimal results.

What molecular weight should I expect for FLAD1 in Western blot analysis?

When using FLAD1 antibodies in Western blot analysis, researchers should expect to observe bands at approximately 50 kDa and 65-70 kDa . The calculated molecular weight based on the amino acid sequence is 49 kDa (446 amino acids) . Alternative splicing of the human FLAD1 gene generates different isoforms of the enzyme FAD synthase, with the ~60 kDa band corresponding to the expected mitochondrial FADS1 and the ~50 kDa band corresponding to the cytosolic FADS2 proteins . When analyzing FLAD1 expression in patient fibroblasts, researchers have also observed a 26 kDa FADS band, which is suggested to contain an intact and functional FADS domain .

What is the recommended storage for FLAD1 antibodies?

FLAD1 antibodies should be stored at -20°C, where they remain stable for one year after shipment . The storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Importantly, aliquoting is unnecessary for -20°C storage, which simplifies laboratory handling protocols . For small quantities (20μl sizes), it should be noted that the preparation may contain 0.1% BSA . Proper storage is essential for maintaining antibody integrity and ensuring consistent experimental results across studies.

How should I optimize Western blot protocols for FLAD1 detection?

For optimal Western blot detection of FLAD1, begin with a dilution range of 1:500-1:1000 of the primary antibody . When designing experiments, consider that FLAD1 antibodies have shown positive detection in various sample types including K-562 cells, HEK-293 cells, HepG2 cells, rat liver tissue, L02 cells, and mouse liver tissue . Sample preparation should be optimized to preserve protein integrity, particularly when investigating both the mitochondrial (~60 kDa) and cytosolic (~50 kDa) isoforms. For loading controls, consider using housekeeping proteins that do not interact with FAD-dependent pathways to avoid potential confounding effects. When analyzing Western blot results from FADS-deficient patients, be aware that the full-length 50 kDa FADS protein levels may be significantly decreased compared to control fibroblasts, while the 26 kDa FADS band with intact FADS domain may remain equally expressed in both patient and control samples .

What controls should I include when using FLAD1 antibodies in immunofluorescence?

When using FLAD1 antibodies for immunofluorescence applications, several essential controls should be incorporated. First, include a negative control by omitting the primary antibody to assess non-specific binding of the secondary antibody. Second, use known positive control samples - HepG2 cells have been validated for positive IF/ICC detection with FLAD1 antibodies . For advanced studies examining subcellular localization, co-staining with organelle-specific markers is recommended, particularly mitochondrial markers to differentiate between the mitochondrial FADS1 and cytosolic FADS2 isoforms. When studying patient samples with FLAD1 mutations, compare staining patterns with wild-type controls to identify potential differences in protein localization or expression levels. For quantitative analysis, standardize image acquisition parameters and perform signal intensity measurements across multiple biological replicates to ensure reliability of results.

How can I verify FLAD1 antibody specificity in my experimental system?

Verifying antibody specificity is crucial for reliable research results. For FLAD1 antibody validation, implement a multi-pronged approach. First, perform Western blot analysis across multiple cell lines (K-562, HEK-293, and HepG2 cells are recommended) to confirm the detection of bands at the expected molecular weights (50 kDa and 65-70 kDa) . Second, consider using FLAD1 knockdown/knockout models as negative controls - the dramatic reduction in FADS protein observed in fibroblasts from patients with truncating FLAD1 variants provides a natural verification system . Third, for advanced validation, perform peptide competition assays using the immunogen (FLAD1 fusion protein Ag5267) to confirm binding specificity . Finally, cross-validate results using alternative detection methods such as mass spectrometry to confirm protein identity. Remember that FLAD1 antibodies have been experimentally verified to show reactivity with human, mouse, and rat samples .

How can FLAD1 antibodies be used to study metabolic disorders?

FLAD1 antibodies serve as valuable tools for investigating metabolic disorders, particularly Multiple Acyl-CoA Dehydrogenase Deficiency (MADD). For research protocols, begin with patient fibroblast cultures where Western blot analysis using FLAD1 antibodies (1:500-1:1000 dilution) can reveal significantly decreased full-length 50 kDa FADS protein levels compared to control samples . This approach allows quantification of protein expression levels, which can be correlated with enzymatic activity measurements. Complementary assays should include determination of FAD synthesis rate and cellular content of flavin cofactors (FAD, FMN, and riboflavin). In published cases, patient fibroblasts showed dramatic reduction in FADS protein with corresponding reduction in FAD synthesis rate and cellular FAD content . Additionally, assess downstream effects on FAD-dependent enzymes by measuring levels of mitochondrial flavoproteins including very long-chain acyl-CoA dehydrogenase (VLCAD), short-chain acyl-CoA dehydrogenase (SCAD), and electron transport flavoprotein (ETF) subunit proteins .

What is the significance of FLAD1 in cancer research?

FLAD1 has emerged as a significant molecule in cancer research, with particular relevance as a potential biomarker. Multiple studies have demonstrated that FLAD1 is overexpressed in various cancer types, especially breast cancer . When designing cancer research studies involving FLAD1, consider that expression levels vary across cancer subtypes - higher FLAD1 expression has been associated with HER+ status, p53 mutation, nodal involvement, NPI stage 3, basal-like phenotype, and triple-negative breast cancer . Age and ethnic factors also correlate with expression levels; patients aged 21-40 years and those of African-American descent show higher FLAD1 expression . For experimental approaches, incorporate tissue microarrays with FLAD1 antibody staining to evaluate expression across tumor samples, correlating results with clinicopathological features. Additionally, survival analysis can determine the prognostic value of FLAD1 expression in different cancer types, potentially identifying patient subgroups that might benefit from targeted therapeutic approaches.

How do FLAD1 mutations affect cellular metabolism and how can this be studied?

FLAD1 mutations significantly impact cellular metabolism by disrupting FAD synthesis, which subsequently affects multiple FAD-dependent enzymes and metabolic pathways. To study these effects, researchers should implement a comprehensive approach combining protein analysis, metabolite measurement, and functional assays. Western blot analysis using FLAD1 antibodies can quantify FADS protein levels, while spectrophotometric techniques can measure FAD synthesis rates and cellular FAD content . In patient fibroblasts with truncating FLAD1 variants, FAD synthesis impairment results in significant reduction of cellular FAD content (60.5 pmol/mg compared to 111.7-171.2 pmol/mg in controls) . Interestingly, FMN and riboflavin levels are also reduced (to 44% and 33% of control values, respectively), suggesting a regulatory metabolic response to FADS impairment . For functional analysis, measure the activity of FAD-dependent enzymes including ETF and ETFQO, as their deficiency leads to MADD. Additionally, researchers should investigate mitochondrial function through respirometry and assess the therapeutic potential of riboflavin supplementation, which has shown efficacy in some FLAD1-related disorders.

How can FLAD1 antibodies be used in co-immunoprecipitation studies?

FLAD1 antibodies have been successfully employed in co-immunoprecipitation (CoIP) studies to investigate protein-protein interactions involving FADS . For effective CoIP protocols, optimize cell lysis conditions to preserve native protein complexes - non-denaturing buffers containing mild detergents (0.1-0.5% NP-40 or Triton X-100) are recommended. Pre-clear lysates with protein A/G beads to reduce non-specific binding. For immunoprecipitation, use 2-5 μg of FLAD1 antibody per 500 μg of total protein, incubating overnight at 4°C. After washing steps, analyze precipitated complexes by Western blot, probing for both FLAD1 and suspected interaction partners. Potential interaction candidates include proteins involved in FAD metabolism and FAD-dependent enzymes. Negative controls should include irrelevant antibodies of the same isotype and pre-immune serum. For validation of novel interactions, consider reciprocal CoIP experiments and additional methodologies such as proximity ligation assays or mass spectrometry analysis of immunoprecipitated complexes.

What approaches can be used to study the dual localization of FLAD1 isoforms?

The dual localization of FLAD1 isoforms (mitochondrial FADS1 and cytosolic FADS2) presents a complex research challenge that requires sophisticated experimental approaches. Begin with subcellular fractionation to physically separate mitochondrial and cytosolic compartments, followed by Western blot analysis using FLAD1 antibodies to detect the ~60 kDa (FADS1) and ~50 kDa (FADS2) isoforms in their respective fractions . For imaging studies, perform co-immunofluorescence with FLAD1 antibodies (1:200-1:800 dilution) and compartment-specific markers (e.g., MitoTracker for mitochondria) . To investigate isoform-specific functions, design siRNA or CRISPR-Cas9 constructs targeting exons specific to each isoform. Advanced techniques include proximity labeling methods such as BioID or APEX2 to identify compartment-specific interaction partners. For studying the dynamic regulation of isoform expression, employ quantitative PCR with isoform-specific primers under various cellular conditions (e.g., metabolic stress, hypoxia). Additionally, investigate the potential shuttling of FADS proteins between compartments using live-cell imaging with fluorescently tagged FLAD1 constructs.

How can I integrate FLAD1 expression data with other biomarkers in cancer research?

Integrating FLAD1 expression data with other biomarkers in cancer research requires sophisticated bioinformatic and experimental approaches. Begin by leveraging public databases such as Oncomine, cBioPortal, UALCAN, and TNMplot to analyze FLAD1 expression across cancer types and correlate with clinical parameters . For breast cancer specifically, stratify FLAD1 expression analysis by molecular subtypes (HER2 status, p53 mutation, basal-like, triple-negative) to identify patterns of co-expression with established biomarkers . Experimentally, design tissue microarrays for multiplex immunohistochemistry with FLAD1 antibodies alongside antibodies for established biomarkers. For functional studies, implement FLAD1 overexpression or knockdown in cancer cell lines and assess the impact on established cancer hallmarks and biomarker expression. Advanced network analysis can reveal FLAD1-associated gene signatures and pathways - the LinkedOmics database is particularly useful for this purpose . Additionally, explore the relationship between FLAD1 and its related microRNAs, which may have prognostic value in breast cancer. For translational relevance, develop prediction models incorporating FLAD1 with other biomarkers to improve diagnostic accuracy and treatment stratification.

What are common pitfalls when working with FLAD1 antibodies and how can they be addressed?

Several challenges may arise when working with FLAD1 antibodies. First, non-specific bands in Western blot applications can be addressed by optimizing antibody dilution (start with 1:500-1:1000) , increasing blocking time, and using high-quality blocking agents. If multiple bands appear, verify whether they represent different FLAD1 isoforms (50 kDa, 65-70 kDa, and potentially 26 kDa) or non-specific binding. For weak signals, extend primary antibody incubation time to overnight at 4°C and optimize protein loading amounts. In immunofluorescence applications, high background staining can be minimized by extending blocking time and optimizing antibody dilution (1:200-1:800 is recommended) . When signals are inconsistent across experiments, standardize sample preparation protocols and consider using fresh antibody aliquots. For patient samples with FLAD1 mutations, be aware that full-length protein may be significantly reduced or absent, requiring longer exposure times or more sensitive detection methods . To address cross-reactivity concerns, validate specificity using FLAD1 knockdown/knockout controls and perform peptide competition assays with the immunogen (FLAD1 fusion protein Ag5267) .

How should I interpret contradictory FLAD1 expression data across different experimental platforms?

When faced with contradictory FLAD1 expression data across different experimental platforms, a systematic analytical approach is essential. First, consider inherent differences between platforms - antibody-based methods detect protein levels while PCR or RNA-seq measure transcript abundance, which may not directly correlate due to post-transcriptional regulation. Second, evaluate antibody specificity and whether different antibodies target distinct epitopes or isoforms of FLAD1 - the 14118-1-AP antibody recognizes multiple FLAD1 isoforms including the 50 kDa and 65-70 kDa variants . Third, assess sample preparation methods, as subcellular localization differences between mitochondrial FADS1 and cytosolic FADS2 may affect detection in certain fractionation protocols . When comparing patient data, consider disease heterogeneity and treatment status - FLAD1 expression in cancers varies by molecular subtype, with higher expression in HER+, p53 mutant, and triple-negative breast cancers . For quantitative comparisons across platforms, normalize data using multiple reference genes or proteins and employ statistical methods that account for platform-specific variations. Finally, validate key findings using orthogonal techniques - combining Western blot, immunofluorescence, and mass spectrometry can provide a more comprehensive understanding of FLAD1 expression patterns.

What considerations are important when studying FLAD1 in patient-derived samples?

When studying FLAD1 in patient-derived samples, several critical considerations must be addressed. First, ethical approval and informed consent are essential prerequisites, particularly when investigating rare disorders like MADD associated with FLAD1 mutations . Sample collection and processing must be standardized to minimize variability - for fibroblast cultures, document passage number and growth conditions. When analyzing FLAD1 expression, be aware that disease-causing variants may dramatically reduce protein levels, requiring sensitive detection methods . Include appropriate controls matched for age, sex, and tissue type, and consider the impact of patient medication, particularly riboflavin supplementation which can affect FLAD1-related parameters . For genetic analysis, sequence the entire FLAD1 gene to identify potential mutations, noting that biallelic pathogenic variants in FLAD1 have been associated with MADD . When interpreting FAD synthesis rates and FAD cellular content, compare against established reference ranges (control fibroblasts typically show FAD synthesis rates of 3.50-4.37 pmol/min mg and FAD content of 111.7-171.2 pmol/mg) . Finally, consider the broader metabolic context by measuring levels of related metabolites and activities of FAD-dependent enzymes to provide a comprehensive assessment of the functional impact of FLAD1 abnormalities.

How might FLAD1 serve as a therapeutic target in cancer?

FLAD1 shows significant potential as a therapeutic target in cancer based on its overexpression in multiple cancer types, particularly breast cancer . To explore this avenue, researchers should first establish causal relationships between FLAD1 overexpression and cancer progression through knockdown and overexpression studies in relevant cell lines and animal models. Investigate whether inhibiting FLAD1 affects cancer cell viability, proliferation, migration, and resistance to apoptosis. Since FLAD1 encodes FAD synthase, a key enzyme in FAD biosynthesis, targeting its enzymatic activity could disrupt metabolic processes critical for rapidly dividing cancer cells. Design high-throughput screens to identify small molecule inhibitors of FADS with appropriate selectivity profiles. Evaluate combination approaches targeting FLAD1 alongside established therapies, particularly for aggressive subtypes with higher FLAD1 expression such as HER+, p53 mutant, and triple-negative breast cancers . Additionally, explore the potential of FLAD1-targeted antibody-drug conjugates for selective delivery of cytotoxic agents to cancer cells overexpressing FLAD1. Consider developing FLAD1 expression assays for patient stratification to identify those most likely to benefit from FLAD1-targeted therapies.

What novel methodologies might enhance FLAD1 research in the future?

Emerging technologies promise to revolutionize FLAD1 research in the coming years. Single-cell proteomics techniques will enable analysis of FLAD1 expression heterogeneity within tissues, providing insights into cell-specific roles. CRISPR-based technologies, including base editing and prime editing, will facilitate precise modification of FLAD1 to study structure-function relationships without complete gene knockout. For visualizing FLAD1 dynamics, super-resolution microscopy combined with split fluorescent protein systems will allow tracking of protein-protein interactions in real-time within living cells. Proximity labeling methods such as TurboID will help map the FLAD1 interactome in different subcellular compartments with temporal resolution. Metabolomic profiling with stable isotope tracing can elucidate the impact of FLAD1 modulation on FAD-dependent metabolic pathways. In structural biology, cryo-electron microscopy will provide high-resolution structures of FADS in complex with interaction partners, informing structure-based drug design. For translational applications, liquid biopsy approaches measuring circulating FLAD1 protein or FLAD1-expressing extracellular vesicles might serve as minimally invasive biomarkers for cancers with FLAD1 overexpression .

How can systems biology approaches integrate FLAD1 into broader metabolic networks?

Systems biology approaches offer powerful frameworks to integrate FLAD1 into broader metabolic networks, enhancing our understanding of its role in health and disease. Begin by constructing comprehensive metabolic models incorporating FAD synthesis and utilization pathways, with FLAD1-encoded FADS as a key node. Multi-omics integration combining proteomics, transcriptomics, and metabolomics data can reveal how FLAD1 expression changes coordinate with other metabolic enzymes under different physiological conditions. Flux balance analysis can predict how FLAD1 perturbations propagate through metabolic networks, identifying potential compensatory mechanisms and vulnerability points. For disease research, compare network perturbations in conditions with altered FLAD1 function, such as MADD and various cancers . Network pharmacology approaches can identify drugs that target multiple nodes within FLAD1-associated pathways for enhanced therapeutic efficacy. Machine learning algorithms applied to large datasets can uncover non-obvious relationships between FLAD1 and seemingly unrelated biological processes. In the clinical context, develop personalized metabolic models incorporating patient-specific FLAD1 variants to predict disease severity and treatment response, particularly for riboflavin supplementation in FLAD1-related disorders .